Annual Net Income
$52.15 M
+$85.52 M+256.33%
31 December 2023
Summary:
Ligand Pharmaceuticals Incorporated annual net profit is currently $52.15 million, with the most recent change of +$85.52 million (+256.33%) on 31 December 2023. During the last 3 years, it has risen by +$55.14 million (+1847.20%). LGND annual net income is now -91.71% below its all-time high of $629.30 million, reached on 31 December 2019.LGND Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Net Income
-$7.17 M
+$44.74 M+86.18%
30 September 2024
Summary:
Ligand Pharmaceuticals Incorporated quarterly net profit is currently -$7.17 million, with the most recent change of +$44.74 million (+86.18%) on 30 September 2024. Over the past year, it has increased by +$3.10 million (+30.19%). LGND quarterly net income is now -101.08% below its all-time high of $666.34 million, reached on 31 March 2019.LGND Quarterly Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Net Income
$45.24 M
+$3.10 M+7.36%
30 September 2024
Summary:
Ligand Pharmaceuticals Incorporated TTM net profit is currently $45.24 million, with the most recent change of +$3.10 million (+7.36%) on 30 September 2024. Over the past year, it has increased by +$28.76 million (+174.52%). LGND TTM net income is now -94.08% below its all-time high of $764.38 million, reached on 31 March 2019.LGND TTM Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LGND Net Income Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +256.3% | +30.2% | +174.5% |
| 3 y3 years | +1847.2% | -152.3% | -33.8% |
| 5 y5 years | -63.6% | +53.0% | -92.4% |
LGND Net Income High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -8.7% | +256.3% | -108.3% | +86.2% | -53.0% | +235.6% |
| 5 y | 5 years | -91.7% | +256.3% | -108.3% | +86.2% | -92.8% | +174.0% |
| alltime | all time | -91.7% | +144.2% | -101.1% | +89.7% | -94.1% | +131.1% |
Ligand Pharmaceuticals Incorporated Net Income History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$7.17 M(-86.2%) | $45.24 M(+7.4%) |
| June 2024 | - | -$51.91 M(-160.3%) | $42.14 M(-56.3%) |
| Mar 2024 | - | $86.14 M(+373.6%) | $96.34 M(+84.7%) |
| Dec 2023 | $52.15 M(-256.3%) | $18.19 M(-277.0%) | $52.15 M(+216.4%) |
| Sept 2023 | - | -$10.27 M(-548.6%) | $16.48 M(-39.3%) |
| June 2023 | - | $2.29 M(-94.5%) | $27.16 M(+13.3%) |
| Mar 2023 | - | $41.95 M(-339.9%) | $23.97 M(-171.9%) |
| Dec 2022 | -$33.36 M(-158.4%) | -$17.48 M(-4428.0%) | -$33.36 M(+56.7%) |
| Sept 2022 | - | $404.00 K(-145.1%) | -$21.29 M(+167.1%) |
| June 2022 | - | -$895.00 K(-94.2%) | -$7.97 M(-133.7%) |
| Mar 2022 | - | -$15.38 M(+184.1%) | $23.65 M(-58.6%) |
| Dec 2021 | $57.14 M(-2014.2%) | -$5.42 M(-139.5%) | $57.14 M(-16.4%) |
| Sept 2021 | - | $13.72 M(-55.3%) | $68.31 M(+42.6%) |
| June 2021 | - | $30.73 M(+69.7%) | $47.89 M(+22.0%) |
| Mar 2021 | - | $18.11 M(+214.3%) | $39.25 M(-1415.0%) |
| Dec 2020 | -$2.98 M(-100.5%) | $5.76 M(-186.0%) | -$2.98 M(-81.5%) |
| Sept 2020 | - | -$6.70 M(-130.3%) | -$16.11 M(-34.7%) |
| June 2020 | - | $22.09 M(-191.5%) | -$24.66 M(-59.7%) |
| Mar 2020 | - | -$24.13 M(+227.6%) | -$61.17 M(-109.7%) |
| Dec 2019 | $629.30 M(+339.1%) | -$7.37 M(-51.7%) | $629.30 M(+5.9%) |
| Sept 2019 | - | -$15.25 M(+5.8%) | $594.18 M(-12.2%) |
| June 2019 | - | -$14.42 M(-102.2%) | $676.80 M(-11.5%) |
| Mar 2019 | - | $666.34 M(-1668.5%) | $764.38 M(+433.3%) |
| Dec 2018 | $143.32 M(+1041.5%) | -$42.48 M(-163.1%) | $143.32 M(-19.8%) |
| Sept 2018 | - | $67.36 M(-7.9%) | $178.79 M(+49.2%) |
| June 2018 | - | $73.16 M(+61.6%) | $119.86 M(+127.2%) |
| Mar 2018 | - | $45.28 M(-745.9%) | $52.75 M(+320.2%) |
| Dec 2017 | $12.56 M(-867.5%) | -$7.01 M(-183.2%) | $12.55 M(-23.6%) |
| Sept 2017 | - | $8.43 M(+39.1%) | $16.44 M(+81.4%) |
| June 2017 | - | $6.06 M(+19.3%) | $9.06 M(-386.2%) |
| Mar 2017 | - | $5.08 M(-262.5%) | -$3.17 M(+93.4%) |
| Dec 2016 | -$1.64 M(-100.7%) | -$3.13 M(-397.4%) | -$1.64 M(-120.9%) |
| Sept 2016 | - | $1.05 M(-117.0%) | $7.83 M(-96.2%) |
| June 2016 | - | -$6.17 M(-193.4%) | $205.94 M(-12.6%) |
| Mar 2016 | - | $6.61 M(+4.2%) | $235.68 M(+2.5%) |
| Dec 2015 | $229.82 M(+1811.4%) | $6.34 M(-96.8%) | $229.82 M(-0.3%) |
| Sept 2015 | - | $199.16 M(+745.2%) | $230.54 M(+606.0%) |
| June 2015 | - | $23.56 M(+3025.2%) | $32.65 M(+205.7%) |
| Mar 2015 | - | $754.00 K(-89.3%) | $10.68 M(-11.2%) |
| Dec 2014 | $12.02 M(+5.3%) | $7.05 M(+451.2%) | $12.02 M(+75.8%) |
| Sept 2014 | - | $1.28 M(-19.6%) | $6.84 M(-9.1%) |
| June 2014 | - | $1.59 M(-24.1%) | $7.52 M(-37.4%) |
| Mar 2014 | - | $2.10 M(+12.2%) | $12.02 M(+5.3%) |
| Dec 2013 | $11.42 M(-2267.0%) | $1.87 M(-4.9%) | $11.42 M(+7.6%) |
| Sept 2013 | - | $1.97 M(-67.7%) | $10.61 M(+25.5%) |
| June 2013 | - | $6.09 M(+307.4%) | $8.46 M(-5224.2%) |
| Mar 2013 | - | $1.50 M(+40.6%) | -$165.00 K(-68.7%) |
| Dec 2012 | -$527.00 K(-105.4%) | $1.06 M(-647.9%) | -$527.00 K(-117.0%) |
| Sept 2012 | - | -$194.00 K(-92.3%) | $3.10 M(-448.6%) |
| June 2012 | - | -$2.53 M(-323.2%) | -$888.00 K(-172.8%) |
| Mar 2012 | - | $1.13 M(-75.8%) | $1.22 M(-87.4%) |
| Dec 2011 | $9.71 M(-193.7%) | $4.69 M(-212.2%) | $9.71 M(+1.9%) |
| Sept 2011 | - | -$4.18 M(+890.0%) | $9.53 M(+411.4%) |
| June 2011 | - | -$422.00 K(-104.4%) | $1.86 M(-6.9%) |
| Mar 2011 | - | $9.63 M(+113.7%) | $2.00 M(-119.3%) |
| Dec 2010 | -$10.37 M(+432.5%) | $4.50 M(-138.0%) | -$10.37 M(-12.4%) |
| Sept 2010 | - | -$11.84 M(+4084.8%) | -$11.84 M(-755.6%) |
| June 2010 | - | -$283.00 K(-89.7%) | $1.81 M(+329.0%) |
| Mar 2010 | - | -$2.75 M(-190.6%) | $421.00 K(-121.6%) |
| Dec 2009 | -$1.95 M | $3.04 M(+68.4%) | -$1.95 M(-97.4%) |
| Sept 2009 | - | $1.80 M(-208.1%) | -$74.61 M(-21.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2009 | - | -$1.67 M(-67.4%) | -$94.54 M(-4.8%) |
| Mar 2009 | - | -$5.12 M(-92.7%) | -$99.30 M(+1.2%) |
| Dec 2008 | -$98.11 M(-134.8%) | -$69.63 M(+284.1%) | -$98.11 M(+335.1%) |
| Sept 2008 | - | -$18.13 M(+181.9%) | -$22.55 M(+610.0%) |
| June 2008 | - | -$6.43 M(+63.5%) | -$3.18 M(-192.5%) |
| Mar 2008 | - | -$3.93 M(-166.2%) | $3.43 M(-98.8%) |
| Dec 2007 | $281.69 M(-987.4%) | $5.94 M(+375.8%) | $281.69 M(-32.5%) |
| Sept 2007 | - | $1.25 M(+589.5%) | $417.11 M(+4.0%) |
| June 2007 | - | $181.00 K(-99.9%) | $400.95 M(+4.2%) |
| Mar 2007 | - | $274.32 M(+94.1%) | $384.81 M(+297.5%) |
| Dec 2006 | -$31.74 M(-12.8%) | $141.36 M(-1047.5%) | $96.80 M(-304.7%) |
| Sept 2006 | - | -$14.92 M(-6.5%) | -$47.29 M(+22.4%) |
| June 2006 | - | -$15.96 M(+16.6%) | -$38.65 M(+22.3%) |
| Mar 2006 | - | -$13.69 M(+402.8%) | -$31.61 M(-13.1%) |
| Dec 2005 | -$36.40 M(-19.4%) | -$2.72 M(-56.7%) | -$36.40 M(+122.7%) |
| Sept 2005 | - | -$6.28 M(-29.6%) | -$16.34 M(-42.8%) |
| June 2005 | - | -$8.92 M(-51.7%) | -$28.56 M(-31.5%) |
| Mar 2005 | - | -$18.47 M(-206.6%) | -$41.70 M(-7.6%) |
| Dec 2004 | -$45.14 M(-53.2%) | $17.33 M(-193.7%) | -$45.14 M(-60.9%) |
| Sept 2004 | - | -$18.50 M(-16.2%) | -$115.54 M(+6.9%) |
| June 2004 | - | -$22.07 M(+0.7%) | -$108.13 M(+10.3%) |
| Mar 2004 | - | -$21.91 M(-58.7%) | -$98.06 M(+1.7%) |
| Dec 2003 | -$96.47 M(+84.6%) | -$53.07 M(+378.6%) | -$96.47 M(+38.2%) |
| Sept 2003 | - | -$11.09 M(-7.6%) | -$69.79 M(+6.1%) |
| June 2003 | - | -$12.00 M(-41.0%) | -$65.75 M(-0.4%) |
| Mar 2003 | - | -$20.32 M(-23.0%) | -$66.00 M(+26.3%) |
| Dec 2002 | -$52.26 M(+21.5%) | -$26.39 M(+274.5%) | -$52.26 M(+34.3%) |
| Sept 2002 | - | -$7.05 M(-42.5%) | -$38.92 M(-1.8%) |
| June 2002 | - | -$12.25 M(+86.3%) | -$39.62 M(+4.3%) |
| Mar 2002 | - | -$6.58 M(-49.6%) | -$37.99 M(-11.6%) |
| Dec 2001 | -$42.99 M(-40.6%) | -$13.05 M(+68.6%) | -$42.99 M(+0.8%) |
| Sept 2001 | - | -$7.74 M(-27.0%) | -$42.64 M(-11.7%) |
| June 2001 | - | -$10.62 M(-8.3%) | -$48.30 M(-10.8%) |
| Mar 2001 | - | -$11.58 M(-8.8%) | -$54.15 M(-24.2%) |
| Dec 2000 | -$72.38 M(-3.1%) | -$12.70 M(-5.2%) | -$71.47 M(-12.4%) |
| Sept 2000 | - | -$13.40 M(-18.6%) | -$81.59 M(-5.7%) |
| June 2000 | - | -$16.46 M(-43.1%) | -$86.48 M(-2.9%) |
| Mar 2000 | - | -$28.91 M(+26.7%) | -$89.03 M(+19.1%) |
| Dec 1999 | -$74.72 M(-36.6%) | -$22.82 M(+24.7%) | -$74.72 M(-19.3%) |
| Sept 1999 | - | -$18.30 M(-3.7%) | -$92.60 M(-23.2%) |
| June 1999 | - | -$19.00 M(+30.1%) | -$120.60 M(+1.3%) |
| Mar 1999 | - | -$14.60 M(-64.1%) | -$119.00 M(+0.9%) |
| Dec 1998 | -$117.90 M(+17.7%) | -$40.70 M(-12.1%) | -$117.90 M(-18.9%) |
| Sept 1998 | - | -$46.30 M(+166.1%) | -$145.30 M(+31.4%) |
| June 1998 | - | -$17.40 M(+28.9%) | -$110.60 M(+6.8%) |
| Mar 1998 | - | -$13.50 M(-80.2%) | -$103.60 M(+3.4%) |
| Dec 1997 | -$100.20 M(+168.6%) | -$68.10 M(+487.1%) | -$100.20 M(+128.2%) |
| Sept 1997 | - | -$11.60 M(+11.5%) | -$43.90 M(+7.9%) |
| June 1997 | - | -$10.40 M(+3.0%) | -$40.70 M(+1.0%) |
| Mar 1997 | - | -$10.10 M(-14.4%) | -$40.30 M(+8.0%) |
| Dec 1996 | -$37.30 M(-41.9%) | -$11.80 M(+40.5%) | -$37.30 M(+10.0%) |
| Sept 1996 | - | -$8.40 M(-16.0%) | -$33.90 M(-0.3%) |
| June 1996 | - | -$10.00 M(+40.8%) | -$34.00 M(-48.1%) |
| Mar 1996 | - | -$7.10 M(-15.5%) | -$65.50 M(+2.0%) |
| Dec 1995 | -$64.20 M(+136.9%) | -$8.40 M(-1.2%) | -$64.20 M(+3.0%) |
| Sept 1995 | - | -$8.50 M(-79.5%) | -$62.30 M(+3.7%) |
| June 1995 | - | -$41.50 M(+615.5%) | -$60.10 M(+131.2%) |
| Mar 1995 | - | -$5.80 M(-10.8%) | -$26.00 M(-4.1%) |
| Dec 1994 | -$27.10 M | -$6.50 M(+3.2%) | -$27.10 M(+31.6%) |
| Sept 1994 | - | -$6.30 M(-14.9%) | -$20.60 M(+44.1%) |
| June 1994 | - | -$7.40 M(+7.2%) | -$14.30 M(+107.2%) |
| Mar 1994 | - | -$6.90 M | -$6.90 M |
FAQ
- What is Ligand Pharmaceuticals Incorporated annual net profit?
- What is the all time high annual net income for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated annual net income year-on-year change?
- What is Ligand Pharmaceuticals Incorporated quarterly net profit?
- What is the all time high quarterly net income for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated quarterly net income year-on-year change?
- What is Ligand Pharmaceuticals Incorporated TTM net profit?
- What is the all time high TTM net income for Ligand Pharmaceuticals Incorporated?
- What is Ligand Pharmaceuticals Incorporated TTM net income year-on-year change?
What is Ligand Pharmaceuticals Incorporated annual net profit?
The current annual net income of LGND is $52.15 M
What is the all time high annual net income for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high annual net profit is $629.30 M
What is Ligand Pharmaceuticals Incorporated annual net income year-on-year change?
Over the past year, LGND annual net profit has changed by +$85.52 M (+256.33%)
What is Ligand Pharmaceuticals Incorporated quarterly net profit?
The current quarterly net income of LGND is -$7.17 M
What is the all time high quarterly net income for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high quarterly net profit is $666.34 M
What is Ligand Pharmaceuticals Incorporated quarterly net income year-on-year change?
Over the past year, LGND quarterly net profit has changed by +$3.10 M (+30.19%)
What is Ligand Pharmaceuticals Incorporated TTM net profit?
The current TTM net income of LGND is $45.24 M
What is the all time high TTM net income for Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated all-time high TTM net profit is $764.38 M
What is Ligand Pharmaceuticals Incorporated TTM net income year-on-year change?
Over the past year, LGND TTM net profit has changed by +$28.76 M (+174.52%)